References
- 1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline - Impurities: Guideline for residualsolvents: Text and Methodology Q3C(R5), Current Step 4 version, London 2011.
- 2. S. Ahuja, Impurities Evaluation of Pharmaceuticals, Marcel Dekker, New York 1998, pp. 1-41.
- 3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline - Validation of Analytical Procedures:Text and Methodology Q2(R1), Current Step 4 version, London 2005.
- 4. S. Gorog, M. Babjak, G. Balogh, J. Brlik, A. Csehi and F. Dravecz, Drug impurity profiling strategies, Talanta 44 (1997) 1517-1526.
- 5. J. Claassen, L. J. Hirsch, R. G. Emerson and S. A. Mayer, Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: A systematic review, Epilepsia 43 (2002) 146-153.
- 6. G. Hsiao, M. Y. Shen, D. S. Chou, Y. Chang, L. W. Lee, C. H. Lin and J. R. Sheu, Mechanisms of antiplatelet and antithrombotic activity of midazolam in in vitro and in vivo studies, Eur. J. Pharmacol.487 (2004) 159-166; DOI: 10.1016/j.ejphar.2004.01.026.
- 7. D. F. Hanley and J. F. Kross, Use of midazolam in the treatment of refractory status epilepticus,Clin. Therap. 20 (1998) 1093-1105.
- 8. E. E. Irvine, S. Cheeta, C. Lovelock and S. E. File, Tolerance to midazolam’s anxiolytic effects after short-term nicotine treatment, Neuropharmacology 40 (2001) 710-716; DOI: 10.1016/S0028-3908(00)00211-2.
- 9. S. L. Eeckhoutd, J. P. Desager, Y. Hormansy, A. J. Winne and R. K. Verbeeck, Sensitive assay for midazolam and its metabolite 1'-hydroxy midazolam in human plasma by capillary high performance liquid chromatography, J. Chromatogr. B 710 (1998) 165-171.
- 10. J. Jurica, M. Dostalek, J. Konecny, Z. Glatz, E. Hadasova and J. Tomandl, HPLC determination of midazolam and its three hydroxy metabolites in perfusion medium and plasma from rats, J. Chromatogr. B 852 (2007) 571-577; DOI: 10.1016/j.jchromb.2007.02.034.
- 11. S. N. Muchohi, S. A. Ward, L. Preston, C. R. J. C. Newton, G. Edwards and G. O. Kokwaro, Determination of midazolam and its major metabolite 1’-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children, J. Chromatogr. B 821 (2005) 1-7; DOI: 10.1016/j.jchromb.2005.03.015.
- 12. X. Xue, M. Huang, H. Xiao, X. Qin, L. Huang, G. Zhong and H. Bi, Rapid and simultaneous measurement of midazolam, 1’-hydroxymidazolam and digoxin by liquid chromatography/ tandem mass spectrometry: Application to an in vivo study to simultaneously measure P-glycoprotein and Cytochrome P450 3A activity, J. Pharm. Biomed. Anal. 55 (2011) 187-193; DOI: 10. 1016/j.jpba.2011.01.018.
- 13. M. R. Shiran, A. Gregory, A. R. Hodjegan, G. T. Tucker and M. S. Lennard, Determination of midazolam and 1’-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment, J. Chromatogr. B. 783 (2003) 303-307; DOI: 10.1016/S1570-0232(02)00673-6.